Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at Jefferies Virtual London Healthcare Conference Transcript

Nov 19, 2020 / 02:40PM GMT
Release Date Price: €57.68 (-2.99%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Hi. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Chris Anzalone, CEO of Arrowhead Pharmaceuticals. We're going to do a fireside chat today. So Chris, thanks for joining us. Maybe to start off, if you want to give a brief intro to Arrowhead for those who may not be familiar with the story.

Christopher R. Anzalone
Arrowhead Pharmaceuticals, Inc. - CEO, President & Director

Sure. So Maury, thank you very much for having us. Of course, thank you, Jefferies, for having us. It's a great pleasure to be here by virtual fire. So look -- so Arrowhead is an RNAi company. Our idea here is to silence target genes that cause disease. I think that we are unique in that we are bringing that technology around the body. I think we've got maybe the largest RNAi clinical pipeline in the business; if not now, shortly. We have said that we think we can get into new cell type every 18 to 24 months, and we said that we can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot